⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Lion TCR and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Lion TCR
↗Singapore, Singapore
Lion TCR is a clinical-stage biotechnology company based in Singapore, specializing in the development of T-cell receptor (TCR)-T cell therapies for viral-related cancers and chronic infectious diseases. Spun off from A*STAR, the company leverages a proprietary TCR-T platform and mRNA technology to engineer patient-specific T cells that target Hepatitis B virus (HBV) antigens.
The company's lead candidate, LioCyx-M (and its variant LioCyx-M004), is primarily focused on treating HBV-related hepatocellular carcinoma (HCC) and chronic hepatitis B. Lion TCR maintains a state-of-the-art GMP production facility and is actively conducting clinical trials to validate the safety and efficacy of its immunotherapy pipeline.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology biotech, Gene Therapy
SIZE & FINANCIALS
Employees:1-50
Founded:2015
Ownership:private
Status:operating
FUNDING
Stage:Series B
Investors:ABC Capital, Westlake Ventures, Smartech, Wanlian Tianze, Wanlian Securities
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Cell therapy, mRNA
Active Trials:9
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Guangzhou Lion TCR Co., Ltd.
Key Partnerships:A*STAR (Scientific foundation and T-Up programme)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Xiaoming Peng - CEO
Tina Wang - Chief Medical Officer
Scientific Founders:Antonio Bertoletti
LINKS
Website:liontcr.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Lion TCR. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.